| Jour | Date | Titre | Effet sur
le cours | CAC40 |
|---|
| 01/04/2024 | 19:00 (J-4) | Receives transparency notification from atlas special opportunities llc | | +0% |
| 26/03/2024 | 19:09 (J-1) | Announces its presence at the paris smallcap event on march 28, 2024. | | +0.41% |
| 25/03/2024 | 19:00 (J-3) | Receives transparency notification from atlas special opportunities llc | | +0% |
| 14/03/2024 | 19:00 (J-1) | Receives transparency notification from atlas special opportunities llc | | +0.29% |
| 08/03/2024 | 18:00 (J-1) | Receives transparency notification from atlas special opportunities llc | | +0.15% |
| 06/03/2024 | 18:00 (J-1) | Receives eur 300,000 in the framework of the atlas funding program tenth tranche fully issued and paid-up | | +0.28% |
| 25/01/2024 | 19:39 (J-1) | Annonce une nouvelle stratégie de réduction des risques et de diversification | | +0.11% |
| 18/01/2024 | 18:00 (J-1) | Receives transparency notification from atlas special opportunities llc | | +1.13% |
| 12/01/2024 | 07:00 | Receives transparency notification from atlas special opportunities llc | 0% | +1.05% |
| 29/12/2023 | 20:15 (J-1) | Avoids bankruptcy, announces board and management changes and enters into binding letter of intent with its main creditor atlas | 0% | +0.11% |
| 04/12/2023 | 18:00 (J-3) | Receives transparency notifications from atlas special opportunities llc | +0% | -0.18% |
| 20/11/2023 | 06:00 | Discloses topline data from kalahari phase 2, part b trial of novel pkal inhibitor thr-149 in diabetic macular edema | 0% | +0.18% |
| 17/11/2023 | 18:00 (J-1) | Receives eur 1.0 million under amended atlas funding program total of eur 3.5 million in unconditional funding allowing company to rea... | 0% | +0.91% |
| 16/11/2023 | 18:00 (J-1) | Receives transparency notification from atlas special opportunities llc | +0% | -0.57% |
| 30/10/2023 | 07:59 | Receives transparency notifications from atlas special opportunities llc | 0% | +0.44% |
| 25/10/2023 | 07:00 | Receives eur 1.5 million under amended atlas funding program total of eur 3.5 million in unconditional funding allowing company to achi... | 0% | +0.31% |
| 23/10/2023 | 19:00 (J-3) | Receives transparency notifications from atlas special opportunities llc | 0% | +0.5% |
| 04/10/2023 | 18:00 (J-1) | Receives transparency notification from atlas special opportunities llc | +0% | +0% |
| 02/10/2023 | 18:00 (J-3) | Publishes first half 2023 results | +0% | -0.94% |
| 28/09/2023 | 18:00 (J-1) | Receives transparency notification from atlas special opportunities llc | 0% | +0.63% |
| 18/09/2023 | 07:03 | Receives first eur 1 million under amended atlas funding program | +0% | -1.39% |
| 07:00 | Receives transparency notifications from atlas special opportunities llc |
| 24/08/2023 | 19:00 (J-1) | Receives transparency notifications from atlas special opportunities llc | +0% | -0.44% |
| 22/08/2023 | 18:00 (J-1) | Receives transparency notification from atlas special opportunities llc | 0% | +0.59% |
| 11/08/2023 | 07:07 | Receives funding of eur one million under atlas special opportunities llc (atlas) funding program | +0% | -1.26% |
| 07:00 | Receives transparency notification from atlas special opportunities llc |
| 08/08/2023 | 18:00 (J-1) | Receives transparency notification from atlas special opportunities llc | -33.33% | -0.69% |
| 27/07/2023 | 18:00 (J-1) | Receives transparency notifications from atlas special opportunities ll | 0% | +2.05% |
| 25/07/2023 | 07:00 | Receives upfront payment of $400,000 following oncurious asset license by vib | +0% | -0.16% |
| 17/07/2023 | 18:00 (J-3) | Receives transparency notification from atlas special opportunities llc | +0% | -1.12% |
| 03/07/2023 | 07:00 | Receives transparency notifications from atlas special opportunities llc | +0% | -0.18% |
| 23/06/2023 | 07:00 | Receives transparency notification from atlas special opportunities llc | +0% | -0.55% |
| 19/06/2023 | 18:00 (J-3) | Receives transparency notification from atlas special opportunities llc | +50% | -1.01% |
| 12/06/2023 | 07:00 | Finalizes enrollment in kalahari phase 2, part b trial of novel pkal inhibitor thr-149 in diabetic macular edema | 0% | +0.52% |
| 01/06/2023 | 07:00 | To participate in upcoming conferences | -25% | +0.55% |
| 22/05/2023 | 18:00 (J-3) | Receives transparency notification from atlas special opportunities llc | +0% | -0.18% |
| 16/05/2023 | 19:00 (J-1) | Announces results of the annual shareholders' meeting of 2 may 2023 | +0% | -0.16% |
| 28/04/2023 | 18:00 (J-1) | Issues eur 2.0 million in bonds for tranche 1 (b) of the funding program with atlas special opportunities llc | +20% | +0.1% |
| 17/04/2023 | 18:00 (J-3) | Receives transparency notification from atlas special opportunities llc | +0% | -0.28% |
| 10/03/2023 | 18:00 (J-1) | Receives transparency notification from negma group | +0% | -1.3% |
| 02/03/2023 | 07:01 | Announces subscription agreement with atlas providing the company with up to €20 million in funding | -14.29% | +0.69% |
| 07:00 | Funding program between oxurion and negma ends |
| 20/02/2023 | 18:00 (J-3) | Receives transparency notifications from negma group | +0% | -0.16% |
| 13/02/2023 | 18:29 (J-3) | Receives transparency notifications | -12.5% | +1.11% |
| 06/02/2023 | 18:00 (J-3) | Receives transparency notifications from negma group | -11.76% | -1.34% |
| 27/01/2023 | 07:00 | Provides further details concerning the second amendment to negma funding program | +-4.55% | |
| 14/12/2022 | 07:00 | Announces the continuation of kalahari phase 2, part b study in diabetic macular edema following interim analysis | -7.69% | -0.21% |
| 17/11/2022 | 07:00 | Receives transparency notifications based on new denominator | -25.69% | -0.47% |
| 07/11/2022 | 19:00 (J-3) | Receives transparency notification from fidelity management & research company llc | -16.67% | +0% |
| 19/10/2022 | 18:00 (J-1) | To participate in upcoming investor conferences | -25% | -0.43% |
| 25/08/2022 | 18:00 (J-1) | To present at upcoming scientific and investor conferences | +18.09% | -0.08% |
| 12/07/2022 | 18:00 (J-1) | Announces presentations at upcoming scientific and investor conferences | -1.23% | +0.8% |
| 03/06/2022 | 07:00 | Announces two upcoming presentations at the macula society 45th annual meeting | +13.53% | -0.23% |
| 11/04/2022 | 06:00 | Announces upcoming pre-clinical data presentation on thr-687 for the treatment of diabetic macular edema at the 2022 association for res... | -4.01% | +0.12% |
| 28/03/2022 | 07:00 | To participate in needham virtual healthcare conference | +4.25% | +0.54% |
| 22:12 (J-3) | Publishes 2021 annual report |
| 18/03/2022 | 19:00 (J-1) | Receives transparency notifications from fidelity management & research company llc and novartis pharma ag | +1.48% | +0.12% |
| 07/03/2022 | 09:00 | Successfully closes eur >10 million in private placement | +-0.43% | -1.31% |
| 03/03/2022 | 07:00 | Successfully raises eur >10 million from leading us and european healthcare investors in a private equity placement | +3.32% | -1.84% |
| 22/02/2022 | 07:00 | Announces 2021 full year results and 2022 outlook | -9.24% | -0.01% |
| 14/02/2022 | 07:00 | Announces new data on thr-149 phase 2 clinical trial (“kalahari”) in dme at the angiogenesis, exudation, and degeneration 2022 confe... | -2.49% | -2.27% |
| 11/02/2022 | 07:00 | Announces upcoming presentation on thr-149 phase 2 clinical trial (“kalahari”) at the angiogenesis, exudation, and degeneration 2022... | -2% | -1.27% |
| 08/02/2022 | 07:00 | To participate in the 2022 bio ceo and investor conference | +2.4% | +0.27% |
| 18/01/2022 | 07:00 | To participate in the 10th edition of degroof petercam's healthcare conference | +0.11% | -0.94% |
| 07/01/2022 | 07:52 | Achève le recrutement des patients pour la prochaine phase de l'essai de traitement des complications oculaires liées au diabète. | +-0.22% | -0.42% |
| 06/12/2021 | 00:00 | International diabetes federation virtual congress | -1.56% | +1.48% |
| 24/11/2021 | 06:29 | To present at the ophthalmology day at btig | +1.41% | |
| 22/11/2021 | 07:36 | Obtient un financement par emprunt de 11 millions de dollars | +-1.66% | |
| 06:00 | Secures eur 10 million convertible bond financing from kreos capital and pontifax ventures |
| 15/11/2021 | 08:06 | Administre le premier patient de la deuxième partie de l'essai sur l''dème maculaire diabétique | -0.68% | +0.53% |
| 04/11/2021 | 07:00 | Announces initiation of equity analyst coverage by h.c. wainwright with a “buy” recommendation | -0.89% | +0.53% |
| 14/10/2021 | 00:00 | Q3 2021 publication évolution de l'activité | 0.63% | +1.33% |
| 13/10/2021 | 12:56 | Administre un premier patient dans le cadre d'un essai sur l''dème maculaire diabétique | -0.83% | +0.75% |
| 06:00 | Announces first patient dosed in its phase 2 study evaluating thr-687 for the treatment of diabetic macular edema (dme) |
| 05/10/2021 | 07:00 | To present at the lytham partners fall 2021 investor conference | +3.61% | +1.52% |
| 30/09/2021 | 10:43 | Le médicament d'oxurion contre l''dème maculaire diabétique présente un profil de sécurité favorable l'action bondit de 19 %. | +9.45% | -0.62% |
| 06:00 | Announces positive results from part a of phase 2 study evaluating thr-149 for treatment of diabetic macular edema (dme) |
| 08/09/2021 | 07:00 | To present clinical and pre-clinical data at upcoming euretina 2021 virtual congress | +0.98% | -0.85% |
| 17/08/2021 | 07:00 | Publication of positive phase 1 clinical data evaluating thr-687 for treatment of dme in ophthalmology science, the american academy of ... | +5.04% | -0.28% |
| 16/08/2021 | 07:00 | Journal of pharmacokinetics and pharmacodynamics highlights desirable pk/pd profiles of thr-687 and thr-149 | +4.25% | -0.83% |
| 25/06/2021 | 06:00 | To focus resources on clinical assets thr-687 and thr-149 | +0.8% | -0.12% |
| 10/06/2021 | 06:00 | Confirms institutional review board approval and submission of the investigational new drug application to the fda to start phase 2 stud... | +3.6% | -0.26% |
| 08/06/2021 | 06:00 | Completes patient enrollment for part a of phase 2 study evaluating thr-149 for treatment of diabetic macular edema (dme) | -0.2% | +0.11% |
| 17/05/2021 | 06:29 | Appoints tom graney, cfa as chief executive officer | +0.2% | -0.28% |
